Histologically confirmed diagnosis of localised prostate cancer (clinical stage T1-3b, N0-1, M0 and a Gleason score of 6-10).
Scheduled to undergo curative-intent treatment involving neoadjuvant androgen deprivation therapy (ADT) for a duration of at least 3 months, alongside radiotherapy.
Recruited prior to, or within the first 2 weeks of, initiating ADT.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Written medical clearance to participate from the treating oncologist.
Sufficient proficiency in English to comprehend study instructions.
Provision of written informed consent.
You may not be if
Evidence of distant metastases (M1).
Uncontrolled cardiovascular conditions (e.g., uncontrolled hypertension, unstable angina, or a myocardial infarction within the past 6 months).
Musculoskeletal pathologies or conditions that would preclude the safe execution of resistance exercise.
A known history of autoimmune disease.
Current use of chronic systemic corticosteroids or other immunosuppressive agents.
Engagement in structured resistance exercise within the preceding 3 months.
Clareo Health | Resistance Exercise, IL-7 and Immune Phenotypes in Prostate Cancer
